Home Biotechnology F. Hoffmann-La Roche Ltd
F

F. Hoffmann-La Roche Ltd

Profile managed by Bizz Id
Switzerland 500+ employees 1896

Description

Roche is a healthcare company with Pharmaceuticals and Diagnostics divisions combining medicines, diagnostic tests and digital solutions. It works in oncology, neurology, immunology and infectious diseases, among other areas. It serves patients in over 100 countries.

Products

45 products
Afimkibart

RG6631. mAb targeting TL1A. Ulcerative colitis and Crohn's disease in Phase 3; atopic dermatitis and rheumatoid arthritis in Phase 2; MASH in Phase 1b.

Under development

Finished product (FDF)

Verified on 2026-10-21

Afimkibart: see suppliers →

Astegolimab

RG6149. COPD. Phase 3.

Under development

Finished product (FDF)

Verified on 2026-10-21

Astegolimab: see suppliers →

Atezolizumab

Brand: Tecentriq. Anti-PD-L1 cancer immunotherapy; intravenous and subcutaneous. NSCLC and SCLC, hepatocellular carcinoma, urothelial cancer, PD-L1-positive TNBC, BRAF V600 melanoma and alveolar soft part sarcoma. Filings in dMMR/MSI-H colon and oesophageal cancer.

Comercializado (agencia no indicada); Aprobado EE. UU. (MIBC ctDNA+, 2026)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Atezolizumab: see suppliers →

Bevacizumab

Brand: Avastin. Monoclonal antibody targeting VEGF-A. Colorectal, non-small cell lung, kidney, ovarian, cervical and breast cancer; glioblastoma. Neurofibromatosis type 2 approved June 2026.

Aprobado EE. UU.; Aprobado Europa; Aprobado Japón

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Bevacizumab: see suppliers →

Cevostamab

RG6160. Bispecific anti-FcRH5/CD3. Relapsed/refractory multiple myeloma (2-4L). Phase 3.

Under development

Finished product (FDF)

Verified on 2026-10-21

Cevostamab: see suppliers →

Clesitamig

DLL3 trispecific. Solid tumors. Phase 1. Chugai programme.

Under development

Finished product (FDF)

Verified on 2026-10-21

Clesitamig: see suppliers →

Codrituzumab

Hepatocellular carcinoma. Phase 1. Chugai programme.

Under development

Finished product (FDF)

Verified on 2026-10-21

Codrituzumab: see suppliers →

Crovalimab

Brand: PiaSky. Recycling monoclonal antibody inhibiting C5; subcutaneous every four weeks. Paroxysmal nocturnal haemoglobinuria. Phase 3 in atypical haemolytic uraemic syndrome.

Aprobado EE. UU.; Aprobado UE; Aprobado Reino Unido; Aprobado Japón; Aprobado China

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Crovalimab: see suppliers →

Dornase alfa

Brand: Pulmozyme. Recombinant human deoxyribonuclease 1. Improves lung function in cystic fibrosis.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Dornase alfa: see suppliers →

Emicizumab

Brand: Hemlibra. Bispecific factor IXa- and factor X-directed antibody. Prophylaxis in haemophilia A with or without factor VIII inhibitors. Phase 3 in type 3 von Willebrand disease.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Emicizumab: see suppliers →

Emugrobart

RG6237 (GYM329). Recycling and antigen-sweeping anti-latent myostatin monoclonal antibody. Obesity. Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

Emugrobart: see suppliers →

Enzelkitug

RG6411. Anti-CCR8 antibody. Solid tumors. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

Enzelkitug: see suppliers →

Epoetin beta

Brand: NeoRecormon. Anaemia due to chronic kidney disease, chemotherapy-induced anaemia, prevention of anaemia in premature babies and pre-surgery blood donation.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Epoetin: see suppliers →

Faricimab

Brand: Vabysmo. Bispecific antibody neutralising Ang-2 and VEGF-A, intravitreal. Neovascular AMD, diabetic macular edema and macular edema after retinal vein occlusion. Phase 3 in myopic CNV.

Aprobado EE. UU.; Aprobado UE; Aprobado Japón; Aprobado Reino Unido; Aprobado FDA (jeringa precargada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Faricimab: see suppliers →

Glofitamab

Brand: Columvi. CD20xCD3 T-cell engaging bispecific antibody. Relapsed or refractory diffuse large B-cell lymphoma after two or more lines. Phase 3 in first line and in mantle cell lymphoma.

Aprobado FDA (aprobación acelerada); Autorización condicional UE

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Glofitamab: see suppliers →

Methoxy polyethylene glycol-epoetin beta

Brand: Mircera. Stimulates red blood cell production. Symptomatic anaemia associated with chronic kidney disease in adults.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Methoxy polyethylene glycol-epoetin: see suppliers →

Mosunetuzumab

Brand: Lunsumio. CD20xCD3 T-cell engaging bispecific antibody. Relapsed or refractory follicular lymphoma after two or more lines. Phase 3 in follicular lymphoma and DLBCL; SC formulation in Phase 2 in SLE.

Aprobado UE; Aprobado EE. UU.

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Mosunetuzumab: see suppliers →

Obinutuzumab

Brand: Gazyva/Gazyvaro. Engineered anti-CD20 monoclonal antibody. Chronic lymphocytic leukaemia and follicular lymphoma. In development/filed in lupus nephritis, SLE, childhood idiopathic nephrotic syndrome and membranous nephropathy.

Aprobado EE. UU.; Aprobado Europa

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Obinutuzumab: see suppliers →

Ocrelizumab

Brand: Ocrevus. Targets CD20-positive B cells; twice-yearly dosing. Relapsing MS, clinically isolated syndrome (US) and primary progressive MS.

Aprobado FDA; Aprobado Comisión Europea

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ocrelizumab: see suppliers →

Pegozafermin

RG6881. Fibroblast growth factor 21 (FGF21) analog. MASH F2-F3 and F4. Phase 3.

Under development

Finished product (FDF)

Verified on 2026-10-21

Pegozafermin: see suppliers →

Pertuzumab

Brand: Perjeta. Targets the HER2 receptor. Neoadjuvant, adjuvant and advanced HER2-positive breast cancer, with Herceptin and chemotherapy.

Aprobado EE. UU.; Aprobado Europa

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pertuzumab: see suppliers →

Pertuzumab + Trastuzumab (SC)

Brand: Phesgo. Fixed-dose combination of two monoclonal antibodies with hyaluronidase, subcutaneous. Early and metastatic HER2-positive breast cancer.

Aprobado UE; Aprobado EE. UU.

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pertuzumab: see suppliers → · Trastuzumab: see suppliers →

Polatuzumab vedotin

Brand: Polivy. Antibody-drug conjugate targeting CD79b. Diffuse large B-cell lymphoma, first line and relapsed or refractory.

Aprobado EE. UU.; Aprobado UE

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Polatuzumab vedotin: see suppliers →

Prasinezumab

RG7935. Anti-alpha-synuclein antibody. Early Parkinson's disease. Phase 3. Partner: Prothena.

Under development

Finished product (FDF)

Verified on 2026-10-21

Prasinezumab: see suppliers →

Ranibizumab

Brand: Susvimo. VEGF inhibitor, port delivery system. Neovascular age-related macular degeneration (US); diabetic macular edema and diabetic retinopathy in development/filed.

Aprobado EE. UU.

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ranibizumab: see suppliers →

RG6035 (Brainshuttle-CD20)

Brainshuttle construct directed at CD20. Multiple sclerosis. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

RG6209 (VEGF x IL6 DutaFab)

VEGF x IL6 DutaFab dual-target. Diabetic macular edema. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

RG6351 (anti-Tie2 agonist)

Anti-Tie2 agonist. Diabetic macular edema. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

RG6382 (CD19 x CD3)

CD19 x CD3 bispecific. Systemic lupus erythematosus. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

RG6648 (cMET ADC)

cMET antibody-drug conjugate. Solid tumors. Phase 1. Managed by MediLink.

Under development

Finished product (FDF)

Verified on 2026-10-21

RG6730 (p40 x TL1A bispecific)

p40 x TL1A bispecific antibody. Ulcerative colitis. Phase 2b. In collaboration with Pfizer.

Under development

Finished product (FDF)

Verified on 2026-10-21

RG6810 (DLL3 ADC)

DLL3 antibody-drug conjugate. Small cell lung cancer. Phase 1. Managed by Innovent.

Under development

Finished product (FDF)

Verified on 2026-10-21

RG6919 (B7H3 ADC)

B7H3 antibody-drug conjugate. Solid tumors. Phase 1. Managed by MediLink.

Under development

Finished product (FDF)

Verified on 2026-10-21

RG6975 (CDH17 ADC)

CDH17 antibody-drug conjugate. Colorectal cancer. Phase 1. In collaboration with Hansoh Pharma.

Under development

Finished product (FDF)

Verified on 2026-10-21

RG6981 (anti-TSLP:IL33)

Dual-target anti-TSLP:IL33. COPD/asthma. Phase 1. Managed by Qyuns Therapeutics.

Under development

Finished product (FDF)

Verified on 2026-10-21

Rituximab

Brand: MabThera / Rituxan (US, Japan, Canada). Follicular lymphoma, DLBCL, chronic lymphocytic leukaemia, rheumatoid arthritis, pemphigus vulgaris, GPA/MPA.

Aprobado EE. UU.; Aprobado Europa

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Rituximab: see suppliers →

Rituximab (SC)

Brand: MabThera SC / Rituxan Hycela (US). Rituximab hyaluronidase, subcutaneous. Follicular lymphoma, DLBCL and chronic lymphocytic leukaemia.

Aprobado EE. UU.; Aprobado Europa

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Rituximab: see suppliers →

Satralizumab

Brand: Enspryng. Humanised monoclonal antibody targeting the IL-6 receptor; subcutaneous. AQP4 antibody-positive neuromyelitis optica spectrum disorder. Phase 3 in MOGAD, autoimmune encephalitis and thyroid eye disease.

Aprobado UE; Aprobado FDA; Aprobado Japón; Aprobado Canadá; Aprobado Suiza

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Satralizumab: see suppliers →

Tocilizumab

Brand: Actemra/RoActemra. Anti-IL-6 receptor therapy; IV and SC formulations. Rheumatoid arthritis, polyarticular and systemic juvenile idiopathic arthritis, giant cell arteritis, CAR-T-induced cytokine release syndrome and severe or critical COVID-19 in hospitalised patients.

Aprobado UE; Aprobado Reino Unido; Aprobado Japón; Aprobado EE. UU.

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Tocilizumab: see suppliers →

Trastuzumab

Brand: Herceptin. Monoclonal antibody. HER2-positive early and advanced breast cancer, advanced HER2-positive gastric cancer.

Aprobado EE. UU.; Aprobado Europa

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Trastuzumab: see suppliers →

Trastuzumab (SC)

Brand: Herceptin SC / Herceptin Hylecta (US). Trastuzumab hyaluronidase, subcutaneous. HER2-positive early and advanced breast cancer.

Aprobado EE. UU.; Aprobado Europa

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Trastuzumab: see suppliers →

Trastuzumab emtansine

Brand: Kadcyla. Antibody-drug conjugate targeting HER2. Advanced and residual-disease early HER2-positive breast cancer. Phase 3 with atezolizumab in high-risk early breast cancer.

Aprobado EE. UU.; Aprobado UE

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Trastuzumab emtansine: see suppliers →

Trontinemab

RG6102. Brainshuttle bispecific 2+1 monoclonal antibody targeting amyloid-beta. Early Alzheimer's disease. Phase 3.

Under development

Finished product (FDF)

Verified on 2026-10-21

Trontinemab: see suppliers →

Vamikibart

RG6179. Anti-IL-6 mAb. Uveitic macular edema. Phase 3.

Under development

Finished product (FDF)

Verified on 2026-10-21

Vamikibart: see suppliers →

Zemocimig

RG6512 (NXT007). Bispecific targeting factor IXa and factor X. Haemophilia A. Phase 3. Partner: Chugai.

Under development

Finished product (FDF)

Verified on 2026-10-21

Zemocimig: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free